Risk factors
Acumen Pharmaceuticals (ABOS) risk factors
Item 1A of every Acumen Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors77 risks2 new3 dropped10 reworded
Going concern doubt added due to recurring operating losses requiring additional funding. Share issuances and institutional agreements added to stock sale risks. Regulatory and clinical trial uncertainties for lead Alzheimer's candidate sabirnetug remain central.
Filed Mar 26, 2026 - FY2024 10-K risk factors78 risks
Acumen is a clinical-stage biopharmaceutical company focused solely on developing sabirnetug for Alzheimer's disease. The company has incurred substantial operating losses, has no approved products, and relies heavily on third-party manufacturers.
Filed Mar 27, 2025